Results 181 to 190 of about 170,520 (332)

Outcomes After Switching to Faricimab in Neovascular Age‐Related Macular Degeneration: Data From the Fight Retinal Blindness! Registry

open access: yesClinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background We aimed to describe 1‐year outcomes of eyes switched to faricimab from first‐generation vascular endothelial growth factor (VEGF) inhibitors for neovascular age‐related macular degeneration (nAMD) in routine care. Methods Multicentre, observational study of 383 eyes tracked in the Fight Retinal Blindness!
Adrian Hunt   +9 more
wiley   +1 more source

Retinal Viral Gene Therapy: Impact of Route of Administration on Serious Adverse Events—A Systematic Review

open access: yesClinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background To explore the prevalence of serious adverse events (SAEs) associated with retinal viral gene therapy and to examine trends influencing SAE occurrences in human gene therapy surgeries and pre‐clinical animal trials. Methods Literature review was performed to identify peer‐reviewed human and animal studies relevant to viral gene ...
Aubrey Berger   +3 more
wiley   +1 more source

Ocular perfusion and age‐related macular degeneration [PDF]

open access: bronze, 2001
Thomas A. Ciulla   +2 more
openalex   +1 more source

Deep Learning‐Based Detection of Reticular Pseudodrusen in Age‐Related Macular Degeneration

open access: yesClinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background Reticular pseudodrusen (RPD) signify a critical phenotype driving vision loss in age‐related macular degeneration (AMD). This study sought to develop and externally test a deep learning (DL) model to detect RPD on optical coherence tomography (OCT) scans with expert‐level performance.
Himeesh Kumar   +26 more
wiley   +1 more source

Ten‐Year Incidence, Risk Factors and Progression Rate of Macular Atrophy in Neovascular Age‐Related Macular Degeneration

open access: yesClinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background To evaluate the 10‐year cumulative incidence, progression rates, and risk factors for macular atrophy (MA) in neovascular age‐related macular degeneration (nAMD) patients receiving long‐term anti‐vascular endothelial growth factor (VEGF) therapy.
Francesco Romano   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy